Nitnib 50 mg Capsule Washington | Bulk Oncology Exporter from India

Nitnib 50 mg Capsule: Leading Targeted Oncology Sourcing for Global Medical Institutions

Are you seeking a reliable Nitnib 50 mg capsule exporter from India? Ernest Impex, a core division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced antineoplastic agents. We operate a highly specialized, cold-chain-compliant supply chain serving Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), ensuring that life-critical cancer therapies are delivered with 100% pharmaceutical integrity.

Detailed Product Overview: What is Nitnib 50 mg?

Nitnib 50 mg Capsule is an oral multi-targeted tyrosine kinase inhibitor (TKI) containing Sunitinib. Manufactured by Zydus Cadila, a global leader in oncology research, Nitnib is a high-potency formulation designed to interfere with the specific cellular pathways that drive the progression of malignant tumors.

For international B2B procurement, Nitnib 50 mg is a staple in managing advanced solid tumors, particularly those that have progressed despite primary treatments like Imatinib.

Primary Therapeutic Indications

Nitnib 50 mg is clinically utilized globally for the following:

1. Metastatic Renal Cell Carcinoma (mRCC): An essential first-line and secondary treatment for advanced kidney cancer.

2. Gastrointestinal Stromal Tumor (GIST): For patients whose disease has progressed or who are intolerant to previous anti-cancer therapies.

3. Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors where surgical removal is not feasible.

Mechanism of Action: Multi-Pathway Signal Disruption

Nitnib 50 mg operates through a sophisticated "multi-target" biological approach to tumor management:

• Receptor Blockade: Sunitinib inhibits multiple receptor tyrosine kinases (RTKs), specifically targeting the vascular endothelial growth factor receptors (VEGFR-1, -2, and -3) and platelet-derived growth factor receptors (PDGFR-α and -β).

• Anti-Angiogenesis: By inhibiting the VEGFR pathway, Nitnib stops the tumor from developing the new blood vessels required to "feed" its growth.

• Direct Cytotoxicity: It targets KIT and FLT3 proteins, which are critical for the survival and division of cancer cells in the gastrointestinal tract and blood.

• Pathway Suppression: This dual-action—starving the tumor of nutrients while simultaneously halting cell division—makes Nitnib highly effective against metastatic disease.

Administration and Clinical Safety

• Dosage Protocol: Typically taken orally once daily. For GIST and RCC, it is often administered on a 6-week cycle (4 weeks on treatment, 2 weeks off).

• Storage: Store at room temperature (below 30°C). Keep the container tightly closed to protect it from light and moisture.

• Key Clinical Monitoring:

• Blood Pressure: Regular monitoring is required as Sunitinib can cause significant hypertension.

• Thyroid Function: Routine screening for hypothyroidism is standard practice during treatment.

• Blood Glucose: Diabetic patients must monitor blood sugar levels closely, as Nitnib may decrease them significantly.

• Liver & Cardiac Health: Periodic LFTs and ECGs are recommended to ensure systemic safety.

Why Source Nitnib from Ernest Impex?

• Authentic Zydus Oncology Exporter: Direct access to genuine Zydus Cadila inventory, ensuring 100% product authenticity and competitive wholesale pricing for global markets.

• Global Logistics Authority: We specialize in the complex documentation and specialized logistics required for Washington, London, Bangkok, Canberra, Singapore, and Kingston.

• Regulatory Transparency: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and necessary international export permits.

• Supply Chain Resilience: In 2026, we prioritize real-time transparency and secure bulk fulfillment for hospital groups and regional distributors.